MARKETSPERPSLIVE39
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

Medicine

All markets
AI
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Tokens
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.01x
No
1.01x
$1 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.01x
No
1.01x
$1 vol1 market
Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.01x
No
1.01x
$1 vol1 market
Medicine

When will Intellia Therapeutics submit a BLA for Lonvo-z?

before December
--
before November
--
$6 vol6 markets
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before December
--
before November
--
$6 vol6 markets
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before December
--
before November
--
$6 vol6 markets
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.01x
No
1.01x
$3 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.01x
No
1.01x
$3 vol1 market
Eli Lilly

Will the FDA approve VERVE-102?

Before 2030
--
Before 2031
--
$24 vol6 markets
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
--
No
1.01x
$19,005 vol1 market
Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027
2.01x
Before Jan 1, 2027
1.01x
$15 vol5 markets
Medicine

Will the FDA approve camizestrant for advanced breast cancer?

Before Oct 1, 2026
3.18x
Before Jan 1, 2027
1.01x
$9 vol3 markets
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before July 2027
1.01x
Before October 2027
--
$34 vol3 markets
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027
2.81x
Before July 2027
--
$27 vol5 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before November
--
Before September
--
$9 vol3 markets
Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.02x
No
1.01x
$3 vol1 market
Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.02x
No
1.01x
$3 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.02x
No
1.01x
$3 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.02x
No
1.01x
$3 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.02x
No
1.01x
$3 vol1 market